<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387617</url>
  </required_header>
  <id_info>
    <org_study_id>19-011832</org_study_id>
    <nct_id>NCT04387617</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones</brief_title>
  <official_title>Effect of Cannabidiol Oil on Postoperative Pain After Ureteroscopy for Urinary Calculi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if CBD oil has any effect on decreasing&#xD;
      postoperative pain control following ureteroscopy for urinary stone disease, and to determine&#xD;
      if CBD oil has any effect in decreasing the amount of postoperative opioids (commonly used&#xD;
      drug) used by patients after undergoing ureteroscopy for urinary stone disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative Pain intensity</measure>
    <time_frame>3 days post-ureteroscopy</time_frame>
    <description>Patient self-reported pain intensity score using a 100 mm visual analog scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative opioid use</measure>
    <time_frame>3 days post-ureteroscopy</time_frame>
    <description>Total dosage of opioids used by patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ureteric stent symptoms</measure>
    <time_frame>1 and 3 days post-ureteroscopy</time_frame>
    <description>Ureteric stent Symptoms Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects and adverse events</measure>
    <time_frame>3 days post-ureteroscopy</time_frame>
    <description>post operative adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Urinary Stone</condition>
  <arm_group>
    <arm_group_label>CBD Oil Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.</description>
    <arm_group_label>CBD Oil Group</arm_group_label>
    <other_name>Epidiolex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are diagnosed with kidney or ureteral stones confirmed on imaging (CT of&#xD;
             the abdomen and pelvis) and who elect for definitive treatment via ureteroscopy at two&#xD;
             sites within a tertiary care institution.&#xD;
&#xD;
          -  Age 18-75 years of age.&#xD;
&#xD;
          -  Patients of either gender.&#xD;
&#xD;
          -  Patients of all ethnic backgrounds.&#xD;
&#xD;
          -  Capable of giving informed consent.&#xD;
&#xD;
          -  Capable and willing to fulfill the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of chronic pain.&#xD;
&#xD;
          -  Chronic use of opioid or other pain medication (&gt; 12 weeks).&#xD;
&#xD;
          -  Known allergy to CBD oil or other cannabinoids.&#xD;
&#xD;
          -  Known or suspected pregnancy.&#xD;
&#xD;
          -  Inability to give informed consent or unable to meet requirements of the study for any&#xD;
             reason.&#xD;
&#xD;
          -  Bilateral ureteroscopy.&#xD;
&#xD;
          -  Current marijuana, cannabidiol (CBD), or dronabinol use.&#xD;
&#xD;
          -  Liver disease/cirrhosis.&#xD;
&#xD;
          -  Current treatment of seizures with clobazam, valproate, or other antiepileptic&#xD;
             medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Stern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Karen L. Stern</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

